Clinical Trial Update: Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the combination of loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B-cell lymphomas, including DLBCL, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: Universität Münster | Conditions: Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL) | Phase 2 | Status: NOT_YET_RECRUITING